https://www.pharmaradar360.com/article/why-the-fear-of-drugs-in-pregnancy-can-do-its-own-harm-156feeb07df54302Pharma Surgeen2026-07-18T16:08:27.000ZWhy the fear of drugs in pregnancy can do its own harmhttps://www.pharmaradar360.com/article/cathie-wood-just-bet-big-on-this-biotech-stock-bb5632967c745ddePharma Surgeen2026-07-18T14:37:15.000ZCathie Wood Just Bet Big on This Biotech Stockhttps://www.pharmaradar360.com/article/german-biopharma-delegation-explores-nanjing-s-cutting-edge-biotech-sky-vs-valky-88a213a3c2ffbafbPharma Surgeen2026-07-18T14:36:51.000ZGerman Biopharma Delegation Explores Nanjing’s Cutting-Edge Biotech Sky Vs Valkyries (DC9vWSAj2e)https://www.pharmaradar360.com/article/cathie-wood-just-bet-big-on-this-biotech-stock-1f467733559f6d8cPharma Surgeen2026-07-18T14:20:00.000ZCathie Wood Just Bet Big on This Biotech Stockhttps://www.pharmaradar360.com/article/clinical-grade-wearable-for-pharma-and-biotech-market-forecast-report-featuring-28033d626e975807Pharma Surgeen2026-07-18T14:04:00.000ZClinical-Grade Wearable For Pharma And Biotech Market Forecast Report Featuring Segment Analysis And Strategic Industryhttps://www.pharmaradar360.com/article/big-pharma-s-300-billion-patent-problem-fuels-biotech-deals-vettafi-commentaries-f8fb6a70c4eb463aPharma Surgeen2026-07-18T13:41:33.000ZBig Pharma’s $300 Billion Patent Problem Fuels Biotech Deals - VettaFi - Commentarieshttps://www.pharmaradar360.com/article/pakistan-assures-chinese-investors-of-full-backing-for-health-care-pharmaceutica-212f48fcaa8c5ae9Pharma Surgeen2026-07-18T13:19:28.000ZPakistan assures Chinese investors of full backing for health care, pharmaceutical investmentshttps://www.pharmaradar360.com/article/fda-accepts-shionogi-s-snda-to-expand-cefiderocol-use-to-pediatric-patients-with-67cc24b36a43e604Pharma Surgeen2026-07-18T12:46:53.000ZFDA Accepts Shionogi's sNDA to Expand Cefiderocol Use to Pediatric Patients With Drug-Resistant Gram-Negative Infectionshttps://www.pharmaradar360.com/article/pakistan-offers-strong-investment-opportunities-in-pharmaceutical-sector-health-1b5e7b8f0e03ebbePharma Surgeen2026-07-18T11:35:14.000ZPakistan offers strong Investment opportunities in Pharmaceutical sector: health ministerhttps://www.pharmaradar360.com/article/ixj-vs-ibbq-global-healthcare-vs-biotech-which-etf-is-the-better-buy-dae45159c622b680Pharma Surgeen2026-07-18T11:15:15.000ZIXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?https://www.pharmaradar360.com/article/ixj-vs-ibbq-global-healthcare-vs-biotech-which-etf-is-the-better-buy-9f1f4f3c4e881484Pharma Surgeen2026-07-18T11:09:28.000ZIXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?https://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-after-psoriasis-data-and-fda-filing-plans-still-l-abf1e4e198a8bcb6Pharma Surgeen2026-07-18T10:30:21.000ZTakeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervaluedhttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524Pharma Surgeen2026-07-18T09:40:27.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/tak-takeda-pharmaceutical-co-ltd-adr-latest-stock-price-analysis-news-and-tradin-72c844005d989ab2Pharma Surgeen2026-07-18T09:37:42.000ZTAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideashttps://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-07-18T09:04:31.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/catalyst-capital-advisors-llc-acquires-new-shares-in-teva-pharmaceutical-industr-229f96e8e33aa551Pharma Surgeen2026-07-18T08:53:13.000ZCatalyst Capital Advisors LLC Acquires New Shares in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/pakistan-china-pharmaceutical-cooperation-to-accelerate-cpec-2-0-15dec3125fe66db1Pharma Surgeen2026-07-18T08:41:50.000ZPakistan-China pharmaceutical cooperation to accelerate CPEC 2.0https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-on-rare-disease-growth-narrative-and-why-valuatio-bf08c591a6780d73Pharma Surgeen2026-07-18T08:38:16.000ZUltragenyx Pharmaceutical (RARE) On Rare Disease Growth Narrative And Why Valuation Is Back In Focushttps://www.pharmaradar360.com/article/fda-issues-recall-notice-for-pillsbury-bread-rolls-e8f374dec1e3f44ePharma Surgeen2026-07-18T08:30:00.000ZFDA Issues Recall Notice for Pillsbury Bread Rollshttps://www.pharmaradar360.com/article/trump-purge-at-fda-and-usda-triggers-food-safety-brain-drain-211ed6056a9146daPharma Surgeen2026-07-18T08:23:23.000ZTrump purge at FDA and USDA triggers food safety ‘brain drain’https://www.pharmaradar360.com/article/fda-suspends-canteen-licence-at-mumbai-s-kem-hospital-over-hygiene-issues-7a9201496a5cf2e2Pharma Surgeen2026-07-18T08:19:24.000ZFDA Suspends Canteen Licence At Mumbai's KEM Hospital Over Hygiene Issueshttps://www.pharmaradar360.com/article/bessemer-group-inc-increases-stake-in-teva-pharmaceutical-industries-ltd-teva-100fa28de0dda338Pharma Surgeen2026-07-18T08:14:54.000ZBessemer Group Inc. Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/what-does-servier-s-2-5-billion-acquisition-mean-for-day-one-biopharmaceuticals-0c3bfac1807ab1d1Pharma Surgeen2026-07-18T08:13:00.000ZWhat Does Servier's $2.5 Billion Acquisition Mean for Day One Biopharmaceuticalshttps://www.pharmaradar360.com/article/dutch-innovative-pharma-adding-8-5-billion-to-economy-7817d96798d4c09ePharma Surgeen2026-07-18T07:53:35.000ZDutch innovative pharma adding €8.5 billion to economyhttps://www.pharmaradar360.com/article/pakistan-assures-chinese-investors-of-full-backing-for-health-care-pharmaceutica-107de429eae22468Pharma Surgeen2026-07-18T07:41:46.000ZPakistan assures Chinese investors of full backing for health care, pharmaceutical investmentshttps://www.pharmaradar360.com/article/molded-fiber-pharmaceutical-vial-inserts-market-global-industry-analysis-and-opp-6a966b9925245965Pharma Surgeen2026-07-18T06:54:44.000ZMolded Fiber Pharmaceutical Vial Inserts Market : Global Industry Analysis and Opportunity Assessment, 2036https://www.pharmaradar360.com/article/fda-latest-news-us-government-s-food-and-drug-administration-grants-approval-to-a9ef558a5ae0ab40Pharma Surgeen2026-07-18T06:31:05.000ZFDA Latest News: US Government’s Food and Drug Administration Grants Approval to Merck’s Cholesterol Pill Lipfendra – Check Recommended Dosage, Side Effects, Price & Morehttps://www.pharmaradar360.com/article/alzheimer-s-real-world-study-confirms-leqembi-therapy-benefits-62d826e078622239Pharma Surgeen2026-07-18T06:19:43.000ZAlzheimer's: Real-world study confirms Leqembi therapy benefitshttps://www.pharmaradar360.com/article/u-s-biotech-firms-develop-weight-loss-drugs-for-cats-66a3c5c70eed2425Pharma Surgeen2026-07-18T05:47:44.000ZU.S. Biotech Firms Develop Weight-Loss Drugs for Catshttps://www.pharmaradar360.com/article/weekly-buzz-nvs-mrk-win-fda-nod-lly-snaps-up-atai-mane-shines-on-hair-loss-data-c500f4b228138d24Pharma Surgeen2026-07-18T05:19:00.000ZWeekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Datahttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-stock-looks-fairly-valued-with-strong-returns-but-822a9d9ebabf8ef6Pharma Surgeen2026-07-18T04:51:47.000ZCollegium Pharmaceutical (COLL) Stock Looks Fairly Valued With Strong Returns But Mixed Earnings##https://www.pharmaradar360.com/article/fda-raids-two-pmc-hospitals-over-unsafe-drug-dispensing-suspends-10-licences-of-b3fe39cb3bbfd23bPharma Surgeen2026-07-18T04:24:07.000ZFDA raids two PMC hospitals over unsafe drug dispensing; suspends 10 licences of eateries, bakeries and dairieshttps://www.pharmaradar360.com/article/opinion-how-to-stop-china-from-leapfrogging-the-u-s-in-biotech-4642160b390402eaPharma Surgeen2026-07-18T02:47:49.000ZOpinion | How to stop China from leapfrogging the U.S. in biotechhttps://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-derivatives-3aebf063550f73f8Pharma Surgeen2026-07-18T01:51:16.000ZState Street SPDR S&P Biotech ETF (Derivatives)https://www.pharmaradar360.com/article/pharmaceutical-technology-730f50fa58b2765cPharma Surgeen2026-07-18T01:13:53.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/seed-and-series-a-financing-lagged-biotech-s-broader-recovery-in-1h26-c93d9e02fa7c53bePharma Surgeen2026-07-18T00:09:00.000ZSeed and series A financing lagged biotech’s broader recovery in 1H26https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-dff4353c9517921aPharma Surgeen2026-07-18T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-f369a5b5b984fbd4Pharma Surgeen2026-07-18T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-6778f591df4b5965Pharma Surgeen2026-07-18T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-57802c76a463a820Pharma Surgeen2026-07-18T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-3b8d5a112cad464aPharma Surgeen2026-07-18T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-e95469b967954c9ePharma Surgeen2026-07-18T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-c281c059a8678cc4Pharma Surgeen2026-07-18T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-65fc792b0fb84124Pharma Surgeen2026-07-18T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e0c42f98f59bf79dPharma Surgeen2026-07-18T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b0b7a7f224386895Pharma Surgeen2026-07-18T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-764efae23aaa1bcePharma Surgeen2026-07-18T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-ddaf2d269e6de2d0Pharma Surgeen2026-07-18T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-e05a9394e6c2a192Pharma Surgeen2026-07-18T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-6301f6ae59f73124Pharma Surgeen2026-07-18T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/multifocal-vasculitic-acute-ischemic-stroke-secondary-to-tubercular-meningitis-w-b462adb2968340b3Pharma Surgeen2026-07-18T00:00:00.000ZMultifocal Vasculitic Acute Ischemic Stroke Secondary to Tubercular Meningitis with Caseating Parietal Tuberculoma and Cavitary Pulmonary Tuberculosis Co-morbid with Alcohol Dependence: A Rare Clinical Intersectionhttps://www.pharmaradar360.com/article/investigating-intracerebral-hemorrhage-evacuation-procedure-volumes-before-and-a-78275009c526f32dPharma Surgeen2026-07-18T00:00:00.000ZInvestigating Intracerebral Hemorrhage Evacuation Procedure Volumes Before and After the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation III (MISTIE III) Trialhttps://www.pharmaradar360.com/article/etiology-and-clinical-characteristics-of-conductive-hearing-loss-at-a-tertiary-h-52973cf314eeabffPharma Surgeen2026-07-18T00:00:00.000ZEtiology and Clinical Characteristics of Conductive Hearing Loss at a Tertiary Hospital in Sudanhttps://www.pharmaradar360.com/article/modified-ghost-system-combining-action-observation-and-vibration-stimulation-for-6a52988e37b4efb3Pharma Surgeen2026-07-18T00:00:00.000ZModified Ghost System combining action, observation, and vibration stimulation for recovery after distal radius fracture surgery: A single-arm clinical feasibility study protocolhttps://www.pharmaradar360.com/article/prompt-engineering-limitations-preliminary-evaluation-of-large-language-models-f-f2b739b4585d3328Pharma Surgeen2026-07-18T00:00:00.000ZPrompt Engineering Limitations: Preliminary Evaluation of Large Language Models for Psychotherapy Safetyhttps://www.pharmaradar360.com/article/suicide-attempt-risk-in-autism-a-national-ehr-study-of-2-3-million-individuals-ed9d956d0862909ePharma Surgeen2026-07-18T00:00:00.000ZSuicide Attempt Risk in Autism: A National EHR Study of 2.3 Million Individualshttps://www.pharmaradar360.com/article/molecular-genetic-markers-of-ovarian-cancer-a615b28c3aa542b4Pharma Surgeen2026-07-18T00:00:00.000ZMolecular Genetic Markers of Ovarian Cancerhttps://www.pharmaradar360.com/article/evaluation-of-mustard-brassica-juncea-l-hybrids-against-alternaria-blight-incite-41fdc27f4ab192dcPharma Surgeen2026-07-18T00:00:00.000ZEvaluation of Mustard (Brassica juncea L.) Hybrids against Alternaria Blight Incited by Alternaria brassicae under Artificial Inoculation Conditionshttps://www.pharmaradar360.com/article/correlation-and-path-coefficient-analysis-of-yield-and-yield-contributing-traits-cf911880541af850Pharma Surgeen2026-07-18T00:00:00.000ZCorrelation and Path Coefficient Analysis of Yield and Yield-contributing Traits in Bread Wheat (Triticum aestivum L.) Genotypeshttps://www.pharmaradar360.com/article/clinical-considerations-in-intramedullary-headless-screw-fixation-of-metacarpal-29c381c55b00230fPharma Surgeen2026-07-18T00:00:00.000ZClinical considerations in intramedullary headless screw fixation of metacarpal and proximal phalanx fractureshttps://www.pharmaradar360.com/article/neuroinflammatory-regulation-of-fracture-healing-after-traumatic-brain-injury-cl-4c5de338acd9a940Pharma Surgeen2026-07-18T00:00:00.000ZNeuroinflammatory regulation of fracture healing after traumatic brain injury: Clinical evidence and emerging mechanistic insightshttps://www.pharmaradar360.com/article/letter-to-the-editor-kellgren-lawrence-classification-for-knee-osteoarthritis-cl-916c9c9cfb4e9baePharma Surgeen2026-07-18T00:00:00.000ZLetter to the Editor: Kellgren-Lawrence classification for knee osteoarthritis: Clinical value and limitationshttps://www.pharmaradar360.com/article/evolving-analytical-landscapes-in-anticancer-drug-analysis-techniques-challenges-60023db639ea0e5ePharma Surgeen2026-07-18T00:00:00.000ZEvolving Analytical Landscapes in Anticancer Drug Analysis: Techniques, Challenges, and Future Directionshttps://www.pharmaradar360.com/article/digital-biomarkers-and-wearable-devices-in-personalized-management-of-chronic-di-cd182a66799eae4cPharma Surgeen2026-07-18T00:00:00.000ZDigital Biomarkers and Wearable Devices in Personalized Management of Chronic Diseases: Clinical Validity and Limitations.https://www.pharmaradar360.com/article/molecular-and-genetic-heterogeneity-of-malignant-neoplasms-as-the-basis-of-tumor-b061f9d32c473fa2Pharma Surgeen2026-07-18T00:00:00.000ZMolecular And Genetic Heterogeneity of Malignant Neoplasms as the Basis of Tumor Progression, Drug Resistance, and Personalization of Antitumor Therapy.https://www.pharmaradar360.com/article/machine-learning-based-early-prediction-of-hospital-readmission-risk-among-chron-4d275de50c04c861Pharma Surgeen2026-07-18T00:00:00.000ZMachine Learning-Based Early Prediction of Hospital Readmission Risk Among Chronic Disease Patients Using Electronic Health Records: A Comparative Study of Ensemble Learning Modelshttps://www.pharmaradar360.com/article/identification-and-quantification-of-paracetamol-adulteration-in-jamu-pegal-linu-0955360f94ecdea1Pharma Surgeen2026-07-18T00:00:00.000ZIdentification and Quantification of Paracetamol Adulteration in Jamu Pegal Linu by TLC-Densitometryhttps://www.pharmaradar360.com/article/autism-beyond-the-checklist-phenocopies-diagnostic-overshadowing-and-the-clinica-fb777461999bc564Pharma Surgeen2026-07-18T00:00:00.000ZAutism Beyond the Checklist: Phenocopies, Diagnostic Overshadowing, and the Clinical Workuphttps://www.pharmaradar360.com/article/assessment-of-umbilical-artery-middle-cerebral-artery-and-ductus-venosus-doppler-6aadaaa37e5aa929Pharma Surgeen2026-07-18T00:00:00.000ZAssessment of Umbilical Artery, Middle Cerebral Artery, and Ductus Venosus Doppler Changes in Severe Fetal Growth Restriction and Their Impact on Neonatal Outcomes: A Retrospective Observational Studyhttps://www.pharmaradar360.com/article/formulation-optimization-and-evaluation-of-pregabalin-floating-controlled-releas-cdc034eed9941ca4Pharma Surgeen2026-07-18T00:00:00.000ZFORMULATION OPTIMIZATION AND EVALUATION OF PREGABALIN FLOATING CONTROLLED-RELEASE TABLETShttps://www.pharmaradar360.com/article/critical-review-of-commercial-lipsticks-with-respect-to-bis-safety-and-quality-s-d6a155351c11b368Pharma Surgeen2026-07-18T00:00:00.000ZCRITICAL REVIEW OF COMMERCIAL LIPSTICKS WITH RESPECT TO BIS SAFETY AND QUALITY STANDARDShttps://www.pharmaradar360.com/article/design-and-synthesis-of-new-yakuchinone-b-derivatives-as-potential-anti-inflamma-61ffa10062ca42f5Pharma Surgeen2026-07-18T00:00:00.000ZDESIGN AND SYNTHESIS OF NEW YAKUCHINONE B DERIVATIVES AS POTENTIAL ANTI-INFLAMMATORY AGENTShttps://www.pharmaradar360.com/article/employee-well-being-in-healthcare-organizations-and-its-impact-on-organizational-bd02d92ab2d8e8f1Pharma Surgeen2026-07-18T00:00:00.000ZEMPLOYEE WELL-BEING IN HEALTHCARE ORGANIZATIONS AND ITS IMPACT ON ORGANIZATIONAL PERFORMANCE: AN EMPIRICAL STUDYhttps://www.pharmaradar360.com/article/context-adaptive-neurolex-segmentation-algorithm-for-machine-learning-nlp-system-e414d2afcd258aa1Pharma Surgeen2026-07-18T00:00:00.000ZContext-Adaptive Neurolex Segmentation Algorithm for Machine Learning NLP Systemshttps://www.pharmaradar360.com/article/incidental-ovarian-neoplastic-and-tumor-like-lesions-in-hysterectomy-specimens-i-2e7b548e5f4c8ec9Pharma Surgeen2026-07-18T00:00:00.000ZIncidental Ovarian Neoplastic and Tumor-Like Lesions in Hysterectomy Specimens: Incidence, Histopathological Spectrum and Clinical Significance - A Retrospective Observational Study from a Tertiary Care Centrehttps://www.pharmaradar360.com/article/efficacy-of-myofascial-release-in-addition-to-conventional-physiotherapy-for-pla-924f5cfe442950c5Pharma Surgeen2026-07-18T00:00:00.000ZEfficacy of Myofascial Release in Addition to Conventional Physiotherapy for Plantar Fasciitis: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-association-of-braf-single-nucleotide-polymorphism-rs113488022-with-clinical-35a5bb99acd83b85Pharma Surgeen2026-07-18T00:00:00.000ZThe Association of BRAF Single Nucleotide Polymorphism (rs113488022) with Clinical Characteristics and Postoperative Outcomes of Craniopharyngiomahttps://www.pharmaradar360.com/article/orbital-anatomical-variations-between-the-southern-china-and-the-kashi-populatio-3b9bf9b9585b2cf4Pharma Surgeen2026-07-18T00:00:00.000ZOrbital anatomical variations between the Southern China and the Kashi populations based on 3D-CT analysishttps://www.pharmaradar360.com/article/gene-related-retinal-detachment-in-a-young-chinese-cohort-acmg-amp-applicability-6ce0622345b46a74Pharma Surgeen2026-07-18T00:00:00.000ZGene-related retinal detachment in a young Chinese cohort: ACMG/AMP applicability and VUS analysishttps://www.pharmaradar360.com/article/clinical-characteristics-and-prognosis-of-solitary-punctate-chorioretinitis-in-c-3a8f050e81a62651Pharma Surgeen2026-07-18T00:00:00.000ZClinical characteristics and prognosis of solitary punctate chorioretinitis in Chinese patientshttps://www.pharmaradar360.com/article/contralateral-balance-training-improves-postural-control-and-functional-recovery-40185ebd2a65311cPharma Surgeen2026-07-18T00:00:00.000ZContralateral Balance Training Improves Postural Control and Functional Recovery After Arthroscopic Anterior Talofibular Ligament Repair: A Prospective, Randomized, Single-Blind Trialhttps://www.pharmaradar360.com/article/the-effects-of-time-restricted-eating-in-comparison-with-energy-restricted-diet-a0894b8e0d3d50eaPharma Surgeen2026-07-18T00:00:00.000ZThe effects of time-restricted eating in comparison with energy-restricted diet on expression of BMAL-1 and miRNA-let-7f-1-3p genes, circadian rhythm status, sleep quality, metabolic and anthropometric markers in obese women: a study protocol for a randomized controlled clinical trialhttps://www.pharmaradar360.com/article/udder-and-teat-affections-in-female-dromedary-camels-frequency-clinical-findings-152be8d8ce1a607ePharma Surgeen2026-07-18T00:00:00.000ZUdder and teat affections in female dromedary camels: Frequency, clinical findings and treatment outcomeshttps://www.pharmaradar360.com/article/comparative-evaluation-of-led-and-diode-laser-assisted-in-office-tooth-whitening-27d618c6b68d36f0Pharma Surgeen2026-07-18T00:00:00.000ZComparative evaluation of LED- and diode laser-assisted in-office tooth whitening: a pilot randomized clinical studyhttps://www.pharmaradar360.com/article/a-novel-endoscopic-retroperitoneal-approach-for-debridement-in-lumbar-infectious-1e893ab8249b03bdPharma Surgeen2026-07-18T00:00:00.000ZA novel endoscopic retroperitoneal approach for debridement in lumbar infectious spondylodiscitis at L4-5: a clinical series and technical notehttps://www.pharmaradar360.com/article/age-stratified-epidemiological-and-clinical-predictors-of-laboratory-confirmed-m-6aa172dadd8e1460Pharma Surgeen2026-07-18T00:00:00.000ZAge-stratified epidemiological and clinical predictors of laboratory-confirmed measles among suspected cases in Diyarbakır, Türkiye (2012–2024): a test-negative case–control studyhttps://www.pharmaradar360.com/article/the-semmelweis-framework-structuring-evidence-foundations-and-expert-opinion-in-8d5ecaf24d17008cPharma Surgeen2026-07-18T00:00:00.000ZThe Semmelweis Framework: structuring evidence foundations and expert opinion in clinical practice guidelineshttps://www.pharmaradar360.com/article/the-impact-of-diabetes-on-clinical-outcomes-in-acutely-ill-patients-a-study-on-p-69a7c985060ab2d6Pharma Surgeen2026-07-18T00:00:00.000ZThe impact of diabetes on clinical outcomes in acutely ill patients - a study on patients admitted to the emergency departmenthttps://www.pharmaradar360.com/article/clinical-correlates-of-early-post-pci-left-ventricular-ejection-fraction-in-pati-8a92f22d3bdc915ePharma Surgeen2026-07-18T00:00:00.000ZClinical correlates of early post-PCI left ventricular ejection fraction in patients with STEMI: a single-center retrospective studyhttps://www.pharmaradar360.com/article/clinical-predictors-of-pathological-femoral-fractures-in-children-a-retrospectiv-7b5cf1f74b907e71Pharma Surgeen2026-07-18T00:00:00.000ZClinical predictors of pathological femoral fractures in children: a retrospective comparative studyhttps://www.pharmaradar360.com/article/comparison-of-clinical-outcomes-and-biochemical-markers-following-tubular-micros-24df7ed7021612c7Pharma Surgeen2026-07-18T00:00:00.000ZComparison of Clinical Outcomes and Biochemical Markers Following Tubular Microscopic Discectomy Versus Full Endoscopic Discectomy for Lumbar Disc Herniation: A Prospective Randomized Controlled Trialhttps://www.pharmaradar360.com/article/emerging-antibiotics-for-urinary-tract-infections-clinical-implications-for-wome-c6f87ec3e3925847Pharma Surgeen2026-07-18T00:00:00.000ZEmerging Antibiotics for Urinary Tract Infections: Clinical Implications for Women’s Healthhttps://www.pharmaradar360.com/article/from-aspiration-to-admission-understanding-pre-medical-student-perceptions-and-d-3a3b04a172b03211Pharma Surgeen2026-07-18T00:00:00.000ZFrom Aspiration to Admission: Understanding Pre‐Medical Student Perceptions and Decision‐Making Processeshttps://www.pharmaradar360.com/article/perpetual-peril-persistent-prevention-a-lifelong-roadmap-for-post-mi-care-3e607bece7b19272Pharma Surgeen2026-07-18T00:00:00.000ZPerpetual Peril, Persistent Prevention: A Lifelong Roadmap for Post-MI Carehttps://www.pharmaradar360.com/article/carbon-emissions-from-medical-procedures-the-importance-of-harmonised-boundaries-15e4d4e82ea7ad8fPharma Surgeen2026-07-18T00:00:00.000ZCarbon emissions from medical procedures: the importance of harmonised boundaries and balanced interpretationhttps://www.pharmaradar360.com/article/predicting-breast-cancer-pathological-complete-response-with-clinical-and-imagin-7ae404849288971bPharma Surgeen2026-07-18T00:00:00.000ZPredicting breast cancer pathological complete response with clinical and imaging datahttps://www.pharmaradar360.com/article/a-lightweight-integrated-generative-ai-assistant-for-accelerated-early-stage-dru-152950068302fdedPharma Surgeen2026-07-18T00:00:00.000ZA lightweight, integrated generative AI assistant for accelerated early-stage drug discovery on constrained-resource hardwarehttps://www.pharmaradar360.com/article/str-mme-syndrome-the-clinical-and-molecular-spectrum-associated-with-variants-in-25a6d2a01070d3edPharma Surgeen2026-07-18T00:00:00.000ZStrømme syndrome: the clinical and molecular spectrum associated with variants in CENPFhttps://www.pharmaradar360.com/article/optim-a-randomized-phase-ii-trial-of-nivolumab-followed-by-nivolumab-ipilimumab-477595b80560a33dPharma Surgeen2026-07-18T00:00:00.000ZOPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)https://www.pharmaradar360.com/article/the-immediate-and-sustained-benefits-of-two-week-high-frequency-aerobic-exercise-a1734e8029101ec3Pharma Surgeen2026-07-18T00:00:00.000ZThe Immediate and sustained benefits of two-week high-frequency aerobic exercise on depressive symptoms and frontal function in subthreshold depression: A randomized controlled trialhttps://www.pharmaradar360.com/article/safety-of-pharmaceutical-nanosuspensions-in-drug-delivery-evidence-knowledge-gap-79c36494f4fdeacaPharma Surgeen2026-07-18T00:00:00.000ZSafety of Pharmaceutical Nanosuspensions in Drug Delivery: Evidence, Knowledge Gaps, and Safety-By-Design Strategieshttps://www.pharmaradar360.com/article/design-synthesis-and-biological-evaluation-of-a-cathepsin-b-activated-small-mole-fb97fbd0c5487180Pharma Surgeen2026-07-18T00:00:00.000ZDesign, Synthesis, and Biological Evaluation of a Cathepsin B-Activated Small Molecule-Drug Conjugate Targeting AKR1C3 to Enhance Chemotherapeutic Selectivityhttps://www.pharmaradar360.com/article/a-multidatabase-bibliometric-analysis-of-phytochemical-metabolomics-research-in-87523745c2b84fa2Pharma Surgeen2026-07-18T00:00:00.000ZA multidatabase bibliometric analysis of phytochemical metabolomics research in Africa and its implications for equitable drug discoveryhttps://www.pharmaradar360.com/article/impact-of-a-moderate-caloric-deficit-and-aerobic-exercise-on-body-composition-in-61f4798cac5e7ef7Pharma Surgeen2026-07-18T00:00:00.000ZImpact of a Moderate Caloric Deficit and Aerobic Exercise On Body Composition in Obese Patients: A Large Single-arm Quasi-experimental Study Using Bioelectrical Impedance Analysishttps://www.pharmaradar360.com/article/protein-tyrosine-kinase-inhibitors-212f13f301becca0Pharma Surgeen2026-07-18T00:00:00.000ZProtein tyrosine kinase inhibitorshttps://www.pharmaradar360.com/article/entrectinib-rivaroxaban-7087ef222f18ddb3Pharma Surgeen2026-07-18T00:00:00.000ZEntrectinib/Rivaroxabanhttps://www.pharmaradar360.com/article/cocaine-b900925808392f55Pharma Surgeen2026-07-18T00:00:00.000ZCocainehttps://www.pharmaradar360.com/article/carbamazepine-4a37ac37bba2c1bbPharma Surgeen2026-07-18T00:00:00.000ZCarbamazepinehttps://www.pharmaradar360.com/article/global-viral-lower-respiratory-disease-episodes-hospitalisations-and-clinical-ou-828a32259cdc34dfPharma Surgeen2026-07-18T00:00:00.000ZGlobal Viral Lower Respiratory Disease Episodes, Hospitalisations, and Clinical Outcomes by Aetiology, 2010–2021https://www.pharmaradar360.com/article/identifying-adverse-drug-events-in-children-with-congenital-heart-disease-using-211e092c445c5890Pharma Surgeen2026-07-18T00:00:00.000ZIdentifying adverse drug events in children with congenital heart disease using machine learning techniques and multi-domain descriptorshttps://www.pharmaradar360.com/article/treatable-traits-in-bronchiectasis-a-precision-medicine-framework-aligned-with-t-8ddca3240568de87Pharma Surgeen2026-07-18T00:00:00.000ZTreatable Traits in Bronchiectasis: A Precision Medicine Framework Aligned with the 2025 ERS Clinical Practice Guidelineshttps://www.pharmaradar360.com/article/effects-of-plyometric-based-high-intensity-interval-training-on-muscle-to-fat-ra-064a0243732da210Pharma Surgeen2026-07-18T00:00:00.000ZEffects of plyometric-based high-intensity interval training on muscle-to-fat ratio in children: protocol for a randomized controlled trial in primary school settingshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-statins-in-patients-with-liver-cirrhosis-a-systematic-rev-fa317baca3dc8362Pharma Surgeen2026-07-18T00:00:00.000ZEfficacy and Safety of Statins in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysishttps://www.pharmaradar360.com/article/expert-consensus-on-the-clinical-application-of-sulodexide-in-vascular-diseases-e794f46904c24892Pharma Surgeen2026-07-18T00:00:00.000ZExpert Consensus on the Clinical Application of Sulodexide in Vascular Diseaseshttps://www.pharmaradar360.com/article/integrative-analysis-identifies-candidate-biomarkers-for-bladder-cancer-evidence-259f85321a644cb2Pharma Surgeen2026-07-18T00:00:00.000ZIntegrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validationhttps://www.pharmaradar360.com/article/fear-of-nighttime-hypoglycemia-perspectives-of-diabetes-providers-and-caregivers-6e3a2c0140dafaa2Pharma Surgeen2026-07-18T00:00:00.000ZFear of Nighttime Hypoglycemia: Perspectives of Diabetes Providers and Caregivershttps://www.pharmaradar360.com/article/igg4-related-hepatic-disease-unmasking-hepatic-actinomycosis-f0d6ed480a5aaf39Pharma Surgeen2026-07-18T00:00:00.000ZIgG4-Related Hepatic Disease Unmasking Hepatic Actinomycosishttps://www.pharmaradar360.com/article/evaluation-of-the-clinical-efficacy-of-accelerated-photoactivated-chromophore-fo-53b0aa06577c5209Pharma Surgeen2026-07-18T00:00:00.000ZEvaluation of the clinical efficacy of accelerated photoactivated chromophore for keratitis-CXL for early to mid-stage fungal keratitis: a prospective, multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-utility-and-diagnostic-yield-of-duodenal-versus-jejunal-aspirates-for-s-14d8d42178a6d8e0Pharma Surgeen2026-07-18T00:00:00.000ZClinical Utility and Diagnostic Yield of Duodenal Versus Jejunal Aspirates for Small Intestinal Bacterial or Fungal Overgrowthhttps://www.pharmaradar360.com/article/feasibility-acceptability-and-preliminary-effects-of-a-nurse-delivered-self-mana-28ef59f1cad77551Pharma Surgeen2026-07-18T00:00:00.000ZFeasibility, Acceptability, and Preliminary Effects of a Nurse-Delivered Self-Management Program for Individuals with Inflammatory Bowel Disease: A Pilot Randomized Controlled Trialhttps://www.pharmaradar360.com/article/adverse-childhood-experiences-and-sexual-risk-behaviours-associations-with-offli-1a3040490edb3e53Pharma Surgeen2026-07-18T00:00:00.000ZAdverse Childhood Experiences and Sexual Risk Behaviours: Associations with Offline and Online Sexual Activity Among Canadian Youthhttps://www.pharmaradar360.com/article/implementation-of-state-prescription-drug-monitoring-program-mandatory-checking-4cee5bc815bbf9e0Pharma Surgeen2026-07-18T00:00:00.000ZImplementation of State Prescription Drug Monitoring Program Mandatory Checking Requirements and Prescribed Opioid Analgesic Use Among Women With and Without HIV in The Women’s Interagency HIV Study: A Longitudinal Observational Study Using Staggered Adoption Difference-in-differences Analyseshttps://www.pharmaradar360.com/article/risk-of-second-primary-malignancies-after-bladder-cancer-diagnosed-at-a-young-ag-530efa432ba6f7acPharma Surgeen2026-07-18T00:00:00.000ZRisk of second primary malignancies after bladder cancer diagnosed at a young age: a SEER population-based analysishttps://www.pharmaradar360.com/article/stereotactic-radiosurgery-for-treatment-refractory-obsessive-compulsive-disorder-5d55b3bff800c6d4Pharma Surgeen2026-07-18T00:00:00.000ZStereotactic radiosurgery for treatment-refractory obsessive-compulsive disorder: a systematic review of targets, targeting methods, lesion geometry, and clinical outcomeshttps://www.pharmaradar360.com/article/cefepime-susceptibility-testing-in-ampc-hyperproducing-enterobacter-cloacae-comp-3f1fcd6f29580f42Pharma Surgeen2026-07-18T00:00:00.000ZCefepime susceptibility testing in AmpC-hyperproducing Enterobacter cloacae complex: limitations of routine methods and a pragmatic diagnostic approachhttps://www.pharmaradar360.com/article/a-conceptual-regeneration-maintenance-decision-aid-for-class-ii-furcation-involv-b4fad4a540685d39Pharma Surgeen2026-07-18T00:00:00.000ZA conceptual regeneration–maintenance decision aid for class II furcation involvementhttps://www.pharmaradar360.com/article/letter-to-the-editor-regarding-impact-of-gross-tumor-morphology-on-the-clinical-73cf515eac237cc5Pharma Surgeen2026-07-18T00:00:00.000ZLetter to the editor regarding “Impact of gross tumor morphology on the clinical outcomes of colon cancer: multicenter retrospective cohort study”https://www.pharmaradar360.com/article/favorable-clinical-outcomes-of-biologic-and-targeted-therapies-in-refractory-eos-9e85ad1a854bd806Pharma Surgeen2026-07-18T00:00:00.000ZFavorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic reviewhttps://www.pharmaradar360.com/article/predicting-postoperative-coronal-imbalance-in-lenke-1-2-adolescent-idiopathic-sc-11a4f14cdfbff790Pharma Surgeen2026-07-18T00:00:00.000ZPredicting postoperative coronal imbalance in Lenke 1/2 adolescent idiopathic scoliosis: A machine learning model with clinical interpretabilityhttps://www.pharmaradar360.com/article/vancomycert-a-certified-neuro-symbolic-drug-delivery-system-case-study-41aa2dac5e6b3de2Pharma Surgeen2026-07-18T00:00:00.000ZVancomycert: A Certified Neuro-Symbolic Drug Delivery System (Case Study)https://www.pharmaradar360.com/article/progress-report-on-new-epilepsy-treatments-a-summary-of-the-eighteenth-eilat-con-1dc88dc7b44a257cPharma Surgeen2026-07-18T00:00:00.000ZProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( <scp>EILAT XVIII</scp> ). <scp>II</scp> . Treatments in more advanced clinical developmenthttps://www.pharmaradar360.com/article/asymmetric-zn-n-sub-3-sub-o-sub-1-sub-single-atom-sites-promote-hydroxyl-radical-07263de756b48c38Pharma Surgeen2026-07-18T00:00:00.000ZAsymmetric Zn─N ₃ O ₁ Single‐Atom Sites Promote Hydroxyl Radical Generation for Natural‐Light‐Driven Inactivation of Drug‐Resistant Bacteriahttps://www.pharmaradar360.com/article/milind-deora-backs-maha-fda-crackdown-pitches-public-dashboard-for-hygiene-compl-a2b306a58ef075edPharma Surgeen2026-07-17T23:03:29.000ZMilind Deora backs Maha FDA crackdown, pitches public dashboard for hygiene compliancehttps://www.pharmaradar360.com/article/fulcrum-therapeutics-stock-plunges-51-after-ha-d9361e8df153c382Pharma Surgeen2026-07-17T21:52:05.000ZFulcrum Therapeutics stock plunges 51% after ha...https://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-17T21:49:03.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/how-fda-review-of-voxzogo-full-approval-data-at-biomarin-bmrn-has-changed-its-in-d571a9e2b3cea4e2Pharma Surgeen2026-07-17T21:46:18.000ZHow FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Storyhttps://www.pharmaradar360.com/article/famu-appoints-vanessa-b-sheppard-as-dean-of-the-college-of-pharmacy-and-pharmace-c59b46b4885f9b04Pharma Surgeen2026-07-17T21:37:02.000ZFAMU Appoints Vanessa B. Sheppard as Dean of the College of Pharmacy and Pharmaceutical Sciences/ Institute of Public Healthhttps://www.pharmaradar360.com/article/this-week-at-fda-fda-staff-raise-concerns-about-peptide-conflicts-top-democrat-w-1084477f628f89d7Pharma Surgeen2026-07-17T21:33:00.000ZThis Week at FDA: FDA staff raise concerns about peptide conflicts, top Democrat wants DOGE investigation, and morehttps://www.pharmaradar360.com/article/fda-inspects-manit-hostels-after-students-fall-ill-finds-alleged-hygiene-lapses-fe6c86d5ddba4844Pharma Surgeen2026-07-17T21:30:00.000ZFDA Inspects MANIT Hostels After Students Fall Ill, Finds Alleged Hygiene Lapseshttps://www.pharmaradar360.com/article/industry-wants-more-clarity-on-ngs-for-assessing-gene-therapy-safety-bfdaf39e6fc48bc4Pharma Surgeen2026-07-17T21:26:00.000ZIndustry wants more clarity on NGS for assessing gene therapy safetyhttps://www.pharmaradar360.com/article/krystal-biotech-rises-as-investors-lean-on-commercial-momentum-and-pipeline-cata-3e5bfcafa860f8abPharma Surgeen2026-07-17T21:21:00.000ZKrystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalystshttps://www.pharmaradar360.com/article/this-biotech-position-gave-us-gains-in-a-choppy-market-f0c678111b429bdfPharma Surgeen2026-07-17T21:16:00.000ZThis Biotech Position Gave Us Gains In A Choppy Markethttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-underperforms-friday-when-compared-to-com-5d1a3e11283efb3aPharma Surgeen2026-07-17T21:02:00.000ZWest Pharmaceutical Services Inc. stock underperforms Friday when compared to competitorshttps://www.pharmaradar360.com/article/nkgen-biotech-nkgn-alters-collateral-on-5m-credit-facility-e4744ee447dbc5b0Pharma Surgeen2026-07-17T21:01:01.000ZNKGen Biotech (NKGN) alters collateral on $5M credit facilityhttps://www.pharmaradar360.com/article/pharmacyte-biotech-pmcb-cancels-erroneous-stock-option-grant-3c1cdcbca0425ecfPharma Surgeen2026-07-17T21:00:40.000ZPharmaCyte Biotech (PMCB) cancels erroneous stock option granthttps://www.pharmaradar360.com/article/pharmacyte-biotech-pmcb-amends-form-4-to-cancel-option-grant-22a6e1cf4766094dPharma Surgeen2026-07-17T21:00:38.000ZPharmaCyte Biotech (PMCB) amends Form 4 to cancel option granthttps://www.pharmaradar360.com/article/pharmacyte-biotech-pmcb-director-corrects-erroneous-cancelled-option-grant-0f462709c2b80935Pharma Surgeen2026-07-17T21:00:37.000ZPharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option granthttps://www.pharmaradar360.com/article/health-headlines-challenges-outbreaks-and-innovations-6401b9e01b6aafd4Pharma Surgeen2026-07-17T20:56:07.000ZHealth Headlines: Challenges, Outbreaks, and Innovationshttps://www.pharmaradar360.com/article/experts-ending-adequate-provision-would-shut-down-prescription-drug-ads-4bb64e4ad008b4dcPharma Surgeen2026-07-17T20:51:00.000ZExperts: Ending adequate provision would shut down prescription drug adshttps://www.pharmaradar360.com/article/weekly-rundown-biogen-pushes-anti-tau-drug-into-phase-3-after-endpoint-miss-6524dfa1fdbd8a5ePharma Surgeen2026-07-17T20:44:19.000ZWeekly Rundown: Biogen pushes anti-tau drug into Phase 3 after endpoint misshttps://www.pharmaradar360.com/article/novo-nordisk-to-launch-lower-cost-ozempic-copy-in-south-africa-5175e3871e12700aPharma Surgeen2026-07-17T20:39:17.000ZNovo Nordisk to launch lower-cost Ozempic copy in South Africahttps://www.pharmaradar360.com/article/challenges-solutions-to-the-domestic-pharma-production-shift-c0a3f2da19e802b2Pharma Surgeen2026-07-17T20:27:38.000ZChallenges, & Solutions to the Domestic Pharma Production Shifthttps://www.pharmaradar360.com/article/florida-biotech-firm-takes-fda-to-court-over-biden-era-export-delays-5ac82426d8e0c6f4Pharma Surgeen2026-07-17T20:27:23.000ZFlorida Biotech Firm Takes FDA to Court Over Biden Era Export Delayshttps://www.pharmaradar360.com/article/accenture-acn-secures-defense-contract-for-pharmaceutical-solu-0718522f4b0d8127Pharma Surgeen2026-07-17T20:26:15.000ZAccenture (ACN) Secures Defense Contract for Pharmaceutical Soluhttps://www.pharmaradar360.com/article/fda-approves-first-oral-pcsk9-inhibitor-to-lower-ldl-cholesterol-in-adults-with-fbbfda80e9f8fcc4Pharma Surgeen2026-07-17T20:25:01.000ZFDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterolhttps://www.pharmaradar360.com/article/former-biotech-executive-erica-bazerkanian-announces-2026-strategic-expansion-of-78f91067131bbfc2Pharma Surgeen2026-07-17T20:25:01.000ZFormer Biotech Executive Erica Bazerkanian Announces 2026 Strategic Expansion of DTC Apparel Brand Bold&Zealhttps://www.pharmaradar360.com/article/expert-insights-psychedelics-cannabis-drug-policy-shift-50cfa3e321d4d12bPharma Surgeen2026-07-17T20:20:00.000ZExpert Insights: Psychedelics, Cannabis, Drug Policy Shifthttps://www.pharmaradar360.com/article/mass-biotech-fda-to-review-experimental-cancer-drug-after-two-rejections-200-lay-61c6747dccfd2361Pharma Surgeen2026-07-17T19:48:00.000ZMass. biotech: FDA to review experimental cancer drug after two rejections, 200+ layoffshttps://www.pharmaradar360.com/article/gsk-drug-from-2b-deal-sputters-in-phase-3-test-in-chronic-cough-0996e155fc0b5c94Pharma Surgeen2026-07-17T19:47:52.000ZGSK Drug From $2B Deal Sputters in Phase 3 Test in Chronic Coughhttps://www.pharmaradar360.com/article/some-telehealth-glp-1-prescriptions-have-little-clinician-oversight-little-regul-4cc2dde1a6f4c388Pharma Surgeen2026-07-17T19:47:07.000ZSome telehealth GLP-1 prescriptions have little clinician oversight, little regulationhttps://www.pharmaradar360.com/article/what-just-happened-with-day-one-biopharmaceuticals-and-servier-417f07c6e2a98784Pharma Surgeen2026-07-17T19:37:29.000ZWhat Just Happened with Day One Biopharmaceuticals and Servierhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-currently-down-eight-consecutive-days-on-pace-for-long-b4b66f811fe09461Pharma Surgeen2026-07-17T19:35:00.000ZUltragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024 -- Data Talkhttps://www.pharmaradar360.com/article/2025-big-executive-summit-supported-funding-models-for-biotech-35616c09d4d5fe4dPharma Surgeen2026-07-17T19:31:15.000Z2025 BIG Executive Summit: Supported Funding Models for Biotechhttps://www.pharmaradar360.com/article/incyte-profitable-biotech-that-could-be-close-to-exploding-nasdaq-incy-473d4f278716f16cPharma Surgeen2026-07-17T19:21:43.000ZIncyte: Profitable Biotech That Could Be Close To Exploding (NASDAQ:INCY)https://www.pharmaradar360.com/article/pilot-program-to-boost-biotech-manufacturing-careers-1509a662b2715d12Pharma Surgeen2026-07-17T18:42:00.000ZPilot program to boost biotech manufacturing careershttps://www.pharmaradar360.com/article/fda-raids-two-pmc-hospitals-over-unsafe-drug-dispensing-suspends-10-licences-of-ea8bb49df4bfae69Pharma Surgeen2026-07-17T18:37:00.000ZFDA raids two PMC hospitals over unsafe drug dispensing; suspends 10 licences of eateries, bakeries and dhttps://www.pharmaradar360.com/article/north-carolina-receives-29-6-million-settlement-in-pharmaceutical-price-fixing-c-c6fb694b0c04cf45Pharma Surgeen2026-07-17T18:28:38.000ZNorth Carolina receives $29.6 million settlement in pharmaceutical price-fixing conspiracyhttps://www.pharmaradar360.com/article/should-stem-cell-therapies-be-regulated-as-drugs-this-biotech-company-is-taking-8c82a3267cfc8c83Pharma Surgeen2026-07-17T18:25:33.000ZShould stem cell therapies be regulated as drugs? This biotech company is taking the FDA to court.https://www.pharmaradar360.com/article/this-biotech-company-has-spent-nearly-3-years-in-fda-limbo-9b7e81a14d274986Pharma Surgeen2026-07-17T18:25:33.000ZThis Biotech Company Has Spent Nearly 3 Years in FDA Limbohttps://www.pharmaradar360.com/article/uk-biotech-completes-cancer-focused-co-buy-in-17m-deal-9af222c615d70c31Pharma Surgeen2026-07-17T18:21:00.000ZUK Biotech Completes Cancer-Focused Co. Buy In £17M Dealhttps://www.pharmaradar360.com/article/1b-swiss-biotech-establishes-us-headquarters-in-the-queen-city-ea11dc4b49c539aaPharma Surgeen2026-07-17T18:10:36.000Z$1B Swiss biotech establishes US headquarters in the Queen Cityhttps://www.pharmaradar360.com/article/jyong-biotech-ltd-nasdaq-mens-short-interest-down-36-2-in-june-847cb3692cdbf0daPharma Surgeen2026-07-17T18:10:06.000ZJyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 36.2% in Junehttps://www.pharmaradar360.com/article/langham-logistics-leans-into-pharmaceutical-cold-storage-122af90972c655e6Pharma Surgeen2026-07-17T18:00:00.000ZLangham Logistics leans into pharmaceutical cold storagehttps://www.pharmaradar360.com/article/blue-owl-backed-latigo-files-for-ipo-adding-to-biotech-pipeline-cc6ef705c2f8e4b2Pharma Surgeen2026-07-17T17:48:40.000ZBlue Owl-Backed Latigo Files for IPO, Adding to Biotech Pipelinehttps://www.pharmaradar360.com/article/u-s-senators-look-to-investigate-foreign-influence-on-u-s-pharmaceutical-supply-102e0e73dd1a0e8aPharma Surgeen2026-07-17T17:29:32.000ZU.S. Senators Look to Investigate Foreign Influence on U.S. Pharmaceutical Supply Chainshttps://www.pharmaradar360.com/article/asu-callan-jmb-partnership-poised-to-transform-marion-into-national-pharmaceutic-f183cf6c8b4495bdPharma Surgeen2026-07-17T17:27:00.000ZASU, Callan JMB Partnership Poised to Transform Marion into National Pharmaceutical Hubhttps://www.pharmaradar360.com/article/supply-chain-signal-domestic-manufacturing-and-the-german-pricing-standoff-9e3fd0bb9f384872Pharma Surgeen2026-07-17T17:24:19.000ZSupply Chain Signal: Domestic Manufacturing and the German Pricing Standoffhttps://www.pharmaradar360.com/article/lifera-leads-saudi-arabia-s-push-to-become-global-biotech-hub-855a1508fd465c9fPharma Surgeen2026-07-17T17:09:07.000ZLifera leads Saudi Arabia's push to become global biotech hubhttps://www.pharmaradar360.com/article/fda-grants-traditional-approval-to-novartis-s-fabhalta-pharmexec-e8069ae5605d9616Pharma Surgeen2026-07-17T17:08:41.000ZFDA Grants Traditional Approval to Novartis's Fabhalta | PharmExechttps://www.pharmaradar360.com/article/kibow-biotech-honored-with-the-american-association-of-naturopathic-physicians-c-f28f6cc29f642f2bPharma Surgeen2026-07-17T17:05:00.000ZKibow® Biotech Honored with The American Association of Naturopathic Physicians Corporation of the Year Awardhttps://www.pharmaradar360.com/article/u-s-biotech-sector-must-reject-mfn-to-beat-china-expert-op-ed-ac95d9e7d5026d87Pharma Surgeen2026-07-17T16:45:06.000ZU.S. Biotech Sector Must Reject MFN to Beat China: Expert Op-edhttps://www.pharmaradar360.com/article/where-to-invest-now-in-ai-biotech-small-caps-and-gold-220627972efba2a9Pharma Surgeen2026-07-17T16:30:00.000ZWhere To Invest Now In AI, Biotech, Small Caps, And Goldhttps://www.pharmaradar360.com/article/this-novartis-drug-could-help-delay-dialysis-fda-grants-full-approval-789daeff3a2d712fPharma Surgeen2026-07-17T16:19:23.000ZThis Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approvalhttps://www.pharmaradar360.com/article/form-144-collegium-pharmaceutical-for-17-july-by-investing-com-66001307ac5ac730Pharma Surgeen2026-07-17T16:18:38.000ZForm 144 COLLEGIUM PHARMACEUTICAL For: 17 July By Investing.comhttps://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-uganda-722249a0dc860b1fPharma Surgeen2026-07-17T16:13:00.000ZEbola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Ugandahttps://www.pharmaradar360.com/article/bright-path-congratulates-khona-scientific-s-investment-in-strengthening-america-0aa364be1801c381Pharma Surgeen2026-07-17T16:11:00.000ZBRIGHT PATH CONGRATULATES KHONA SCIENTIFIC'S INVESTMENT In STRENGTHENING AMERICA'S PHARMACEUTICAL SUPPLY CHAINhttps://www.pharmaradar360.com/article/blossomhill-eyes-ipo-to-grow-taller-in-crowded-cancer-fields-e07c8f5778d5aab1Pharma Surgeen2026-07-17T16:08:24.000ZBlossomHill eyes IPO to grow taller in crowded cancer fieldshttps://www.pharmaradar360.com/article/bayer-s-heart-failure-drug-bound-for-nhs-on-nice-recommendation-60efc7eb63c78917Pharma Surgeen2026-07-17T16:07:48.000ZBayer’s heart failure drug bound for NHS on NICE recommendationhttps://www.pharmaradar360.com/article/jcvi-statement-on-meningococcal-b-vaccination-in-older-children-and-young-adults-26c1361f3a11f5e2Pharma Surgeen2026-07-17T16:05:32.000ZJCVI statement on meningococcal B vaccination in older children and young adults, 16 July 2026https://www.pharmaradar360.com/article/china-pharmaceutical-innovation-conference-cpic-e98a3a26c3a5f307Pharma Surgeen2026-07-17T16:05:14.000ZChina Pharmaceutical Innovation Conference (CPIC)https://www.pharmaradar360.com/article/fda-raised-conflict-of-interest-concerns-ahead-of-new-peptide-panel-0d05f6525b915b02Pharma Surgeen2026-07-17T16:00:00.000ZFDA raised conflict of interest concerns ahead of new peptide panelhttps://www.pharmaradar360.com/article/forum-exposes-gaps-in-regulatory-ecosystem-faeacd53c1251f88Pharma Surgeen2026-07-17T16:00:00.000ZForum exposes gaps in regulatory ecosystemhttps://www.pharmaradar360.com/article/summit-therapeutics-refocuses-on-oncology-drug-after-antibiotic-sale-8b5d09fc02caeb5fPharma Surgeen2026-07-17T15:56:16.000ZSummit Therapeutics Refocuses on Oncology Drug After Antibiotic Salehttps://www.pharmaradar360.com/article/gsk-shelves-cough-drug-acquired-in-2b-deal-bd9de70ed2418cddPharma Surgeen2026-07-17T15:53:47.000ZGSK shelves cough drug acquired in $2B dealhttps://www.pharmaradar360.com/article/study-expects-plasticware-use-to-increase-7e265d7c915fb457Pharma Surgeen2026-07-17T15:45:05.000ZStudy expects plasticware use to increasehttps://www.pharmaradar360.com/article/cloudbreak-pharma-inc-announces-completion-of-safety-review-by-the-fda-for-cbt-3-65f368ad47aec419Pharma Surgeen2026-07-17T15:40:56.000ZCloudbreak Pharma Inc. Announces Completion Of Safety Review By The FDA For CBT-358 Investigational New Drug Applicationhttps://www.pharmaradar360.com/article/raphael-pharmaceutical-inc-announces-chief-financial-officer-changes-effective-j-f0946ad798ec907ePharma Surgeen2026-07-17T15:36:53.000ZRaphael Pharmaceutical Inc. Announces Chief Financial Officer Changes, Effective July 16, 2026https://www.pharmaradar360.com/article/bio-san-diego-2026-executive-interviews-e07fc300cca2c9a5Pharma Surgeen2026-07-17T15:18:59.000ZBIO San Diego 2026 Executive Interviewshttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-963ee016ca25eb9dPharma Surgeen2026-07-17T15:09:49.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-00ac63488b85ac4aPharma Surgeen2026-07-17T15:02:46.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/guidance-medical-devices-list-of-uk-approved-bodies-a9ce4e9e06b7ac08Pharma Surgeen2026-07-17T15:02:34.000ZGuidance: Medical devices: list of UK approved bodieshttps://www.pharmaradar360.com/article/jasper-therapeutics-3b41362289520222Pharma Surgeen2026-07-17T14:57:45.000ZJasper Therapeuticshttps://www.pharmaradar360.com/article/what-teva-pharmaceutical-industries-teva-s-tev-408-vitiligo-data-and-funding-dea-c66895e4ea971a27Pharma Surgeen2026-07-17T14:55:19.000ZWhat Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholdershttps://www.pharmaradar360.com/article/ion-pair-reagents-market-growth-trajectory-to-2035-analytical-chemistry-demand-a-164f5c4b721864f5Pharma Surgeen2026-07-17T14:51:12.000ZIon-Pair Reagents Market Growth Trajectory to 2035: Analytical Chemistry Demand Accelerates - News and Statisticshttps://www.pharmaradar360.com/article/fda-juggernaut-marches-on-110-year-old-parsi-dairy-farm-s-licence-suspended-bbc27d059c6976a4Pharma Surgeen2026-07-17T14:48:24.000ZFDA Juggernaut Marches On, 110-Year Old Parsi Dairy Farm’s Licence Suspendedhttps://www.pharmaradar360.com/article/the-end-for-gsk-s-chronic-cough-treatment-e2d9feb7b026c38ePharma Surgeen2026-07-17T14:45:27.000ZThe end for GSK’s chronic cough treatmenthttps://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-covered-by-pcv13-2ddf38f53562a4bdPharma Surgeen2026-07-17T14:41:58.000ZPneumococcal disease: cases caused by serotypes covered by PCV13https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-not-covered-by-pcv13-ce6e5496ced9fd89Pharma Surgeen2026-07-17T14:29:51.000ZPneumococcal disease: cases caused by serotypes not covered by PCV13https://www.pharmaradar360.com/article/new-effort-can-help-beat-china-in-biotech-race-if-rfk-jr-doesn-t-hold-it-back-71911de930d1a63ePharma Surgeen2026-07-17T14:00:00.000ZNew effort can help beat China in biotech race — if RFK Jr. doesn’t hold it backhttps://www.pharmaradar360.com/article/inside-the-uk-us-pharmaceutical-supply-chain-deal-b8434d602ad0e1acPharma Surgeen2026-07-17T13:56:12.000ZInside the UK-US Pharmaceutical Supply Chain Dealhttps://www.pharmaradar360.com/article/j-j-s-mark-graham-on-advancing-nipocalimab-as-treatment-for-sle-a3cabf9419b3297aPharma Surgeen2026-07-17T13:55:20.000ZJ&J’s Mark Graham on advancing nipocalimab as treatment for SLEhttps://www.pharmaradar360.com/article/jasper-finds-new-purpose-in-merger-with-kira-while-offloading-tavneos-rival-to-m-a0e76b7dac6e6068Pharma Surgeen2026-07-17T13:54:16.000ZJasper finds new purpose in merger with Kira, while offloading Tavneos rival to Miradorhttps://www.pharmaradar360.com/article/tagrisso-chasing-blossomhill-enters-nasdaq-queue-as-biotech-ipos-flourish-4ceaf0792f5699d3Pharma Surgeen2026-07-17T13:54:00.000ZTagrisso-chasing BlossomHill enters Nasdaq queue as biotech IPOs flourishhttps://www.pharmaradar360.com/article/apha-urges-fda-to-put-patient-safety-first-in-review-of-peptide-substances-d81ff3322f9c1474Pharma Surgeen2026-07-17T13:48:00.000ZAPhA urges FDA to put patient safety first in review of peptide substanceshttps://www.pharmaradar360.com/article/health-news-round-up-vaccination-testosterone-and-neighbourhood-health-935f9761f60cb940Pharma Surgeen2026-07-17T13:42:37.000ZHealth news round-up: vaccination, testosterone and neighbourhood healthhttps://www.pharmaradar360.com/article/fierce-pharma-asia-gsk-merck-adcs-trial-wins-az-s-1-5b-egfr-buy-biotechs-new-pat-32358f6a5cd363c9Pharma Surgeen2026-07-17T13:38:37.000ZFierce Pharma Asia—GSK, Merck ADCs’ trial wins; AZ’s $1.5B EGFR buy; Biotechs’ new patent trickshttps://www.pharmaradar360.com/article/mumbai-s-110-year-old-parsi-dairy-farm-loses-food-licence-after-fda-inspection-44c462fe10297f77Pharma Surgeen2026-07-17T13:31:12.000ZMumbai's 110-Year-Old Parsi Dairy Farm Loses Food Licence After FDA Inspectionhttps://www.pharmaradar360.com/article/update-van-het-document-over-goedkeuringsdatum-van-variaties-hernieuwingen-en-no-316da521f93d2cefPharma Surgeen2026-07-17T13:26:53.000ZUpdate van het document over goedkeuringsdatum van variaties, hernieuwingen en notificaties bij geneesmiddelen voor menselijk gebruikhttps://www.pharmaradar360.com/article/johnson-johnson-to-spend-up-to-750m-restructuring-pharmaceutical-supply-chain-16f5f8bbb2d31d80Pharma Surgeen2026-07-17T13:26:01.000ZJohnson & Johnson to spend up to $750m restructuring pharmaceutical supply chainhttps://www.pharmaradar360.com/article/raphael-pharmaceutical-raph-names-new-cfo-as-chairman-and-cfo-resign-8b40754c5eea7706Pharma Surgeen2026-07-17T13:21:23.000ZRaphael Pharmaceutical (RAPH) names new CFO as chairman and CFO resignhttps://www.pharmaradar360.com/article/biotech-growth-says-eli-lilly-s-2-8bn-swoop-on-ataibeckley-underlines-the-value-e3431c8719546379Pharma Surgeen2026-07-17T13:17:10.000ZBiotech Growth says Eli Lilly's $2.8bn swoop on AtaiBeckley underlines the value of smaller drug developershttps://www.pharmaradar360.com/article/alternative-provider-medical-services-apms-directions-043c2ff68b329a12Pharma Surgeen2026-07-17T13:13:29.000ZAlternative Provider Medical Services (APMS) Directionshttps://www.pharmaradar360.com/article/cencora-s-brent-wilhelm-on-the-inventory-paradox-behind-drug-shortages-64d4ace979f8a1c8Pharma Surgeen2026-07-17T13:09:19.000ZCencora's Brent Wilhelm on the Inventory Paradox Behind Drug Shortageshttps://www.pharmaradar360.com/article/legend-biotech-legn-could-be-60-undervalued-following-carvykti-sales-update-10cb27f4d7d248f8Pharma Surgeen2026-07-17T13:04:32.000ZLegend Biotech (LEGN) Could Be 60% Undervalued Following CARVYKTI Sales Updatehttps://www.pharmaradar360.com/article/cybin-help-advances-psychedelic-depression-drug-to-phase-3-amid-fresh-funding-wh-ed63b59fb2505e70Pharma Surgeen2026-07-17T13:04:32.000ZCybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters?https://www.pharmaradar360.com/article/big-pharma-just-paid-up-to-3-8-billion-for-psychedelic-medicine-and-the-rest-of-50d42ff07d8a029cPharma Surgeen2026-07-17T12:50:00.000ZBig Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Timehttps://www.pharmaradar360.com/article/morning-briefing-biotech-growth-shareholders-signal-opposition-to-fund-manager-g-18e831669f7d47a8Pharma Surgeen2026-07-17T12:45:00.000ZMorning briefing: Biotech Growth shareholders signal opposition to fund manager Geoff Hsu's presence on the board; Saba lifts Gore Street Energy stake; AVI adds to Residential Secure as LIVE deal completes; plus GABIhttps://www.pharmaradar360.com/article/cybin-help-advances-psychedelic-depression-drug-to-phase-3-amid-fresh-funding-wh-a07ab8fbcb43054aPharma Surgeen2026-07-17T12:42:59.000ZCybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters?https://www.pharmaradar360.com/article/corporate-report-human-medicines-regulations-2012-advisory-bodies-annual-report-86ef90e134d27337Pharma Surgeen2026-07-17T12:30:50.000ZCorporate report: Human Medicines Regulations (2012) Advisory Bodies Annual Report 2025https://www.pharmaradar360.com/article/cue-lines-up-new-cmo-and-research-head-chutes-ladders-27a23ee414e8d6a1Pharma Surgeen2026-07-17T12:30:00.000ZCue lines up new CMO and research head—Chutes & Laddershttps://www.pharmaradar360.com/article/worldwide-healthcare-biotech-m-a-made-89-in-15-months-and-is-most-actively-manag-59792c10b2e95ce8Pharma Surgeen2026-07-17T12:17:05.000ZWorldwide Healthcare: Biotech M&A made 89% in 15 months and is "most actively managed" part of our portfoliohttps://www.pharmaradar360.com/article/the-100-000-gamble-on-fda-approvals-sparks-medical-ethics-crisis-edffcb7a9092b17aPharma Surgeen2026-07-17T12:10:29.000ZThe $100,000 Gamble on FDA Approvals Sparks Medical Ethics Crisishttps://www.pharmaradar360.com/article/veradermics-touts-oral-hair-loss-data-as-shares-jump-d63dcc8a8bee8213Pharma Surgeen2026-07-17T12:01:14.000ZVeradermics touts oral hair-loss data as shares jumphttps://www.pharmaradar360.com/article/merge-pacs-7ba5299293452363Pharma Surgeen2026-07-17T12:00:00.000ZMerge PACShttps://www.pharmaradar360.com/article/er-spec-single-use-vaginal-speculum-with-led-light-source-3c914393bef850ffPharma Surgeen2026-07-17T12:00:00.000ZER-Spec Single-Use Vaginal Speculum with LED Light Sourcehttps://www.pharmaradar360.com/article/atellica-ch-urine-albumin-ualb-b86f8a3597265148Pharma Surgeen2026-07-17T12:00:00.000ZAtellica® CH Urine Albumin (UAlb)https://www.pharmaradar360.com/article/4k-uhd-lcd-monitor-127e28651ec63facPharma Surgeen2026-07-17T12:00:00.000Z4K UHD LCD Monitorhttps://www.pharmaradar360.com/article/allergan-aesthetics-receives-approval-for-boey-trenibotulinumtoxine-for-use-in-e-8343323becc4b0d6Pharma Surgeen2026-07-17T12:00:00.000ZAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientshttps://www.pharmaradar360.com/article/amneal-expands-iohexol-injection-portfolio-with-u-s-fda-approval-of-additional-s-4bd84ad6588ffc7ePharma Surgeen2026-07-17T12:00:00.000ZAmneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentationshttps://www.pharmaradar360.com/article/milind-deora-backs-maha-fda-crackdown-pitches-public-dashboard-for-hygiene-compl-ee2c2670b54b3447Pharma Surgeen2026-07-17T11:57:56.000ZMilind Deora backs Maha FDA crackdown, pitches public dashboard for hygiene compliancehttps://www.pharmaradar360.com/article/using-generative-ai-to-support-revision-and-learning-40194585bf2fc528Pharma Surgeen2026-07-17T11:37:17.000ZUsing generative AI to support revision and learninghttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-de-un-lote-del-medicamento-veterinario-tessie-0-c4cb47d9e639f5adPharma Surgeen2026-07-17T11:35:47.000ZLa AEMPS informa de la retirada de un lote del medicamento veterinario Tessie 0,3 mg/ml solución oral para perroshttps://www.pharmaradar360.com/article/tessie-0-3-mg-ml-solucion-oral-para-perros-eu-2-21-276-001-a0744dd7af621e51Pharma Surgeen2026-07-17T11:33:54.000ZTESSIE 0,3 MG/ML SOLUCION ORAL PARA PERROS (EU/2/21/276/001)https://www.pharmaradar360.com/article/theolytics-expands-oxford-biotech-operations-with-new-facility-to-advance-theo-2-0bd655cc14212a80Pharma Surgeen2026-07-17T11:30:54.000ZTheolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapyhttps://www.pharmaradar360.com/article/pattern-hair-loss-study-analyzes-men-under-40-and-men-40-and-older-f93b2da338f37720Pharma Surgeen2026-07-17T11:30:00.000ZPattern hair-loss study analyzes men under 40 and men 40 and olderhttps://www.pharmaradar360.com/article/serum-institute-to-manufacture-promising-tb-vaccine-candidate-under-gates-mri-pa-37619b3303b47544Pharma Surgeen2026-07-17T11:16:10.000ZSerum Institute to manufacture promising TB vaccine candidate under Gates MRI partnershiphttps://www.pharmaradar360.com/article/who-is-tukaram-mundhe-meet-the-ias-officer-with-25-transfers-in-21-years-leading-a72aaeaf54e175c8Pharma Surgeen2026-07-17T11:02:23.000ZWho Is Tukaram Mundhe? Meet the IAS Officer With 25 Transfers In 21 Years Leading Maharashtras Food Safetyhttps://www.pharmaradar360.com/article/la-aemps-informa-sobre-el-nuevo-sistema-de-evaluacion-de-tecnologias-sanitarias-1b67643d2579238ePharma Surgeen2026-07-17T10:59:32.000ZLa AEMPS informa sobre el nuevo Sistema de Evaluación de Tecnologías Sanitarias tras la aprobación del Real Decreto 415/2026https://www.pharmaradar360.com/article/rani-links-with-pegbio-to-grow-oral-obesity-pipeline-871aae4309ac2789Pharma Surgeen2026-07-17T10:41:11.000ZRani links with PegBio to grow oral obesity pipelinehttps://www.pharmaradar360.com/article/2-reasons-to-avoid-bmrn-and-1-stock-to-buy-instead-6daa4d1c5356c13aPharma Surgeen2026-07-17T10:37:50.000Z2 Reasons to Avoid BMRN and 1 Stock to Buy Insteadhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-limited-announces-new-drug-application-for-trastuzumab-1b1895da709f0f6cPharma Surgeen2026-07-17T10:35:45.000ZCSPC Pharmaceutical Group Limited Announces New Drug Application for Trastuzumab Envedotin Injection Accepted by Nmpahttps://www.pharmaradar360.com/article/gsk-abandons-cough-drug-added-in-2bn-bellus-deal-12ec184f2b11da15Pharma Surgeen2026-07-17T10:26:16.000ZGSK abandons cough drug added in $2bn Bellus dealhttps://www.pharmaradar360.com/article/la-aemps-informa-del-robo-y-distribucion-ilegal-de-dos-lotes-de-sensores-dexcom-b6ac66382549252aPharma Surgeen2026-07-17T10:25:04.000ZLa AEMPS informa del robo y distribución ilegal de dos lotes de sensores Dexcom G7https://www.pharmaradar360.com/article/fda-issues-urgent-warning-don-t-eat-taco-bell-lettuce-in-5-states-b36db7e958351097Pharma Surgeen2026-07-17T10:18:16.000ZFDA issues urgent warning: Don't eat Taco Bell lettuce in 5 stateshttps://www.pharmaradar360.com/article/eli-lilly-bets-big-on-psychedelics-with-3-8-billion-takeover-of-ataibeckley-d5f2d92a00ed76adPharma Surgeen2026-07-17T10:16:00.000ZEli Lilly Bets Big on Psychedelics with $3.8 Billion Takeover of AtaiBeckleyhttps://www.pharmaradar360.com/article/sanofi-sues-pfizer-and-moderna-for-patent-infringements-related-to-covid-vaccine-6505ae0e0eba5dc1Pharma Surgeen2026-07-17T10:12:37.000ZSanofi sues Pfizer and Moderna for patent infringements related to COVID vaccineshttps://www.pharmaradar360.com/article/guidance-ai-airlock-sandbox-phase-2-programme-report-73318c57a9ccf366Pharma Surgeen2026-07-17T10:11:27.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/fda-crackdown-restaurant-body-breaks-silence-backs-raids-but-seeks-clear-communi-7275024b05e4d67bPharma Surgeen2026-07-17T10:09:04.000ZFDA crackdown: Restaurant body breaks silence, backs raids but seeks ‘clear communication’https://www.pharmaradar360.com/article/blossomhill-therapeutics-clinical-stage-oncology-biotech-files-for-nasdaq-global-06ea9eeed5096fc2Pharma Surgeen2026-07-17T10:08:00.000ZBlossomHill Therapeutics, Clinical-Stage Oncology Biotech, Files for Nasdaq Global Select Market IPOhttps://www.pharmaradar360.com/article/ph-eur-revises-general-chapter-on-alternative-microbiological-methods-49a12c52a3eedef2Pharma Surgeen2026-07-17T10:00:04.000ZPh. Eur. revises general chapter on alternative microbiological methodshttps://www.pharmaradar360.com/article/gsk-axes-key-cough-drug-candidate-after-phase-3-data-disappoint-1dd70709621a8020Pharma Surgeen2026-07-17T09:46:34.000ZGSK axes key cough drug candidate after phase 3 data disappointhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-says-nmpa-accepts-new-drug-application-for-trastuzumab-enved-b6ee04a40ea01175Pharma Surgeen2026-07-17T09:23:34.000ZCSPC Pharmaceutical Says NMPA Accepts New Drug Application For Trastuzumab Envedotin Injectionhttps://www.pharmaradar360.com/article/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in-d872850514eca694Pharma Surgeen2026-07-17T09:00:00.000ZGSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)https://www.pharmaradar360.com/article/dimerix-snaps-up-mission-s-stalled-phase-2-ready-kidney-disease-candidate-in-292-ebadbf851225c36dPharma Surgeen2026-07-17T09:00:00.000ZDimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M dealhttps://www.pharmaradar360.com/article/while-president-lee-jae-myung-mentioned-the-need-for-a-drug-that-induces-pregnan-f8a381ba1374c52cPharma Surgeen2026-07-17T08:56:24.000ZWhile President Lee Jae Myung mentioned the need for a drug that induces pregnancy suspension, the g..https://www.pharmaradar360.com/article/cspc-pharmaceutical-group-s-stock-price-plummets-by-6-28-dipping-to-8-06-hkd-in-416ca95ed8ff0ad1Pharma Surgeen2026-07-17T08:41:30.000ZCSPC Pharmaceutical Group's Stock Price Plummets by 6.28%, Dipping to 8.06 HKD in Recent Tradinghttps://www.pharmaradar360.com/article/the-israeli-biotech-trying-to-make-damaged-nerves-grow-again-e37e82c32c9afa45Pharma Surgeen2026-07-17T08:40:00.000ZThe Israeli biotech trying to make damaged nerves grow againhttps://www.pharmaradar360.com/article/aman-nna-republic-of-korea-donates-korean-essential-medicines-to-strengthen-heal-f958e75112a19d58Pharma Surgeen2026-07-17T08:38:42.000ZAMAN - NNA - Republic of Korea donates Korean essential medicines to strengthen health cooperation with Lebanonhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-nyse-teva-given-consensus-rating-of-moderate-40b2074aeebf67a5Pharma Surgeen2026-07-17T08:30:58.000ZTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of "Moderate Buy" by Brokerageshttps://www.pharmaradar360.com/article/implementing-reporter-assay-based-mat-for-rapid-pyrogen-detection-bbb10d5d48332f87Pharma Surgeen2026-07-17T08:24:46.000ZImplementing reporter assay-based MAT for rapid pyrogen detectionhttps://www.pharmaradar360.com/article/alnylam-pharmaceuticals-nasdaq-alny-a-value-stock-priced-below-biotech-peers-wit-787a03631e9b3e6cPharma Surgeen2026-07-17T08:10:32.000ZAlnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growthhttps://www.pharmaradar360.com/article/monopar-a-rare-disease-asset-with-heavy-metal-upside-initiating-buy-9c6e90d0e6c1750ePharma Surgeen2026-07-17T07:58:35.000ZMonopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)https://www.pharmaradar360.com/article/fda-approves-first-oral-pcsk9-inhibitor-71ba81b2d9164c3dPharma Surgeen2026-07-17T07:52:08.000ZFDA Approves First Oral PCSK9 Inhibitorhttps://www.pharmaradar360.com/article/qlife-targets-agreement-after-the-summer-098093059108f953Pharma Surgeen2026-07-17T07:45:50.000ZQlife targets agreement after the summerhttps://www.pharmaradar360.com/article/la-aemps-informa-del-riesgo-de-caidas-en-determinadas-gruas-winn-motion-34566e2764379ec1Pharma Surgeen2026-07-17T07:29:59.000ZLa AEMPS informa del riesgo de caídas en determinadas grúas Winn’Motionhttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-returns-to-the-spotlight-ahead-of-key-phase-f889d85265edb8b4Pharma Surgeen2026-07-17T07:17:00.000ZParadigm Biopharmaceuticals (ASX: PAR) Returns to the Spotlight Ahead of Key Phase 3 Trial Milestonehttps://www.pharmaradar360.com/article/topiramate-market-to-reach-usd-39-6-million-by-2036-supported-by-generic-antiepi-bd63fa93f2c9986aPharma Surgeen2026-07-17T07:03:23.000ZTopiramate Market to Reach USD 39.6 Million by 2036, Supported by Generic Antiepileptic Drug Production and Regulatory Compliance | Future Market Insightshttps://www.pharmaradar360.com/article/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-52e0d33b2719579dPharma Surgeen2026-07-17T07:03:11.000ZNew autologous T cell therapy offers hope for children with brain tumorshttps://www.pharmaradar360.com/article/mumbai-s-iconic-parsi-dairy-farm-loses-license-in-maharashtra-fda-crackdown-rs-1-f4f643fe0dd5433fPharma Surgeen2026-07-17T07:02:59.000ZMumbai’s iconic Parsi Dairy Farm loses license in Maharashtra FDA crackdown; Rs 1.9 crore worth adulterated food seizedhttps://www.pharmaradar360.com/article/dimerix-expands-pipeline-with-acquisition-of-phase-2-ready-asset-for-acute-kidne-ada51482882813efPharma Surgeen2026-07-17T06:58:00.000ZDIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURYhttps://www.pharmaradar360.com/article/does-zasocitinib-s-phase-3-success-in-hard-to-treat-psoriasis-areas-change-the-b-5a415b34d16ee3adPharma Surgeen2026-07-17T06:53:52.000ZDoes Zasocitinib’s Phase 3 Success in Hard-to-Treat Psoriasis Areas Change The Bull Case For Takeda Pharmaceutical (TSE:4502)?https://www.pharmaradar360.com/article/la-version-mise-a-jour-du-formulaire-de-demande-d-autorisation-de-mise-sur-le-ma-fc397c76f0cf22f6Pharma Surgeen2026-07-17T06:52:04.000ZLa version mise à jour du formulaire de demande d'autorisation de mise sur le marché est désormais disponible pour les procédures nationales, de reconnaissance mutuelle et décentraliséeshttps://www.pharmaradar360.com/article/annex-1-sterilisation-why-pharma-packaging-strategy-is-changing-d0874f189c71fd8bPharma Surgeen2026-07-17T06:40:43.000ZAnnex 1 sterilisation: Why pharma packaging strategy is changinghttps://www.pharmaradar360.com/article/biotech-growth-trust-portfolio-company-ataibeckley-to-be-acquired-by-eli-lilly-cf0db7612c931a38Pharma Surgeen2026-07-17T06:40:42.000ZBiotech Growth Trust Portfolio Company AtaiBeckley To Be Acquired By Eli Lillyhttps://www.pharmaradar360.com/article/biomarkers-in-nephrology-research-from-exploratory-to-decision-making-tools-2290c940259f3fc1Pharma Surgeen2026-07-17T06:40:16.000ZBiomarkers in Nephrology Research: From Exploratory to Decision-Making Toolshttps://www.pharmaradar360.com/article/us-zinc-prices-hold-steady-in-early-july-as-pharmaceutical-demand-and-supply-cos-5584fb890ab6b4dfPharma Surgeen2026-07-17T06:33:18.000ZUS Zinc Prices Hold Steady in Early July as Pharmaceutical Demand and Supply Costs Support Markethttps://www.pharmaradar360.com/article/gates-mri-serum-institute-of-india-sign-agreement-to-manufacture-tuberculosis-va-bd1656c40c414a4bPharma Surgeen2026-07-17T06:17:00.000ZGates MRI, Serum Institute of India sign agreement to manufacture Tuberculosis Vaccine candidatehttps://www.pharmaradar360.com/article/dxb-boosts-drug-pipeline-and-funding-runway-8ba6e1d18ae53d82Pharma Surgeen2026-07-17T06:13:00.000ZDXB boosts drug pipeline and funding runwayhttps://www.pharmaradar360.com/article/fda-accepts-resubmission-of-camurus-cam2029-nd-acf50a8147f34498Pharma Surgeen2026-07-17T05:56:16.000ZFDA accepts resubmission of Camurus' CAM2029 ND...https://www.pharmaradar360.com/article/west-wst-stock-looks-fair-on-cash-flow-yet-pricey-on-earnings-fc2502658d83384bPharma Surgeen2026-07-17T05:35:17.000ZWest (WST) Stock Looks Fair On Cash Flow Yet Pricey On Earningshttps://www.pharmaradar360.com/article/fda-advisory-no-2026-0800-public-health-warning-against-the-purchase-and-use-of-9c90fb5148c2d5d6Pharma Surgeen2026-07-17T05:31:57.000ZFDA Advisory No.2026-0800 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Hepatitis B Vaccine (rDNA) I.P. (Bevac®) Recombinant HBs Antigen produced in Pichia Pastoris (Yeast) Adult Ten Dose – 10mL”https://www.pharmaradar360.com/article/bio-asia-taiwan-2026-day-3-round-up-biotech-s-next-great-race-begins-where-disco-76d487471fd69b91Pharma Surgeen2026-07-17T05:29:29.000ZBIO Asia–Taiwan 2026 Day 3 Round-Up: Biotech’s Next Great Race Begins Where Discovery Endshttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-07-17T05:11:20.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/50-shades-of-legally-gray-fda-s-juicy-peptide-cliffhanger-70f0114cfd08d7d0Pharma Surgeen2026-07-17T05:00:00.000Z50 Shades of Legally Gray: FDA’s Juicy Peptide Cliffhangerhttps://www.pharmaradar360.com/article/merck-secures-first-ever-oral-cholesterol-drug-approval-from-fda-47cc16e89dc28164Pharma Surgeen2026-07-17T04:59:34.000ZMerck Secures First-Ever Oral Cholesterol Drug Approval from FDAhttps://www.pharmaradar360.com/article/world-syringes-for-agilent-market-analysis-forecast-size-trends-and-insights-8e6810dd2f824fffPharma Surgeen2026-07-17T04:51:13.000ZWorld Syringes for Agilent - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/mumbai-s-parsi-dairy-farm-food-licence-suspended-over-hygiene-and-food-safety-vi-3dde578925879ee3Pharma Surgeen2026-07-17T04:17:00.000ZMumbai's Parsi Dairy Farm food licence suspended over hygiene and food safety violationshttps://www.pharmaradar360.com/article/imported-seafood-mushrooms-canned-food-among-products-subject-to-increased-fda-s-be1195feaef37f74Pharma Surgeen2026-07-17T04:02:27.000ZImported seafood, mushrooms, canned food among products subject to increased FDA scrutinyhttps://www.pharmaradar360.com/article/reversing-ai-drug-discovery-belgian-biotech-sightera-raises-3m-to-learn-from-ext-b2815e249048e134Pharma Surgeen2026-07-17T04:00:34.000ZReversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology firsthttps://www.pharmaradar360.com/article/blsm-ipo-news-cancer-therapies-biotech-blossomhill-therapeutics-files-for-a-100-691f9f3cfc9614a4Pharma Surgeen2026-07-17T04:00:00.000ZBLSM IPO News - Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO